In otolaryngologic surgeries, achieving hemostasis is of paramount importance for reducing associated morbidities. Topical hemostatic agents have been studied mainly in endonasal operations. Its use in other surgeries has been minimally reported. In this "real world data" study, we retrospectively evaluated the surgeries between June 2014 and December 2014, where topical hemostatic agent—Evicel® (Ethicon BioSurgery, US) was used to achieve hemostasis. All the patients were followed till 15 day post operation. The data on Evicel® preparation time, intraoperative blood loss, hemostasis time, length of hospital stay, blood transfusion given, and complications were evaluated. The quality of life was assessed by using discomfort score and it was statistically analyzed for patients underwent surgery for chronic rhinosinusitis and chronic otitis media. The surgical clinical data of 103 patients (63 males and 40 females) were considered for the analysis. In all patients, hemostasis was achieved in less than 1 min. The intraoperative blood loss was between 23 and 99 ml for all surgeries. No postoperative bleeding was reported and blood transfusion was not required for any patients. The hospital stay was 1–2 days. In endonasal surgeries, nasal packing was not required in 36.9% of patients. The discomfort score was statistically improved in patients underwent surgery for chronic rhinosinusits and chronic otitis media (p < 0.001). No complications were reported till day 15 postoperatively. Evicel®, a topical human fibrin sealant found to be effective in achieving hemostasis and for better clinical outcome in various otolaryngologic surgical procedures.